Skip to main navigation Skip to search Skip to main content

European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management

  • Winfried Häuser
  • , David P. Finn
  • , Eija Kalso
  • , Nevenka Krcevski-Skvarc
  • , Hans Georg Kress
  • , Bart Morlion
  • , Serge Perrot
  • , Michael Schäfer
  • , Chris Wells
  • , Silviu Brill
  • Klinikum Saarbrücken
  • Technical University Munich
  • Helsinki University Central Hospital
  • Faculty of Medicine of University Maribor
  • University of Vienna
  • KU Leuven– University Hospital Leuven
  • APHP Hospital Cochin
  • Charité – Universitätsmedizin Berlin
  • Pain Matters Ltd
  • Tel Aviv Medical Center

Research output: Contribution to a Journal (Peer & Non Peer) › Review article › peer-review

165 Citations (Scopus)

Abstract

Cannabis-based medicines are being approved for pain management in an increasing number of European countries. There are uncertainties and controversies on the role and appropriate use of cannabis-based medicines for the management of chronic pain. EFIC convened a European group of experts, drawn from a diverse range of basic science and relevant clinical disciplines, to prepare a position paper to empower and inform specialist and nonspecialist prescribers on appropriate use of cannabis-based medicines for chronic pain. The expert panel reviewed the available literature and harnessed the clinical experience to produce these series of recommendations. Therapy with cannabis-based medicines should only be considered by experienced clinicians as part of a multidisciplinary treatment and preferably as adjunctive medication if guideline-recommended first- and second-line therapies have not provided sufficient efficacy or tolerability. The quantity and quality of evidence are such that cannabis-based medicines may be reasonably considered for chronic neuropathic pain. For all other chronic pain conditions (cancer, non-neuropathic noncancer pain), the use of cannabis-based medicines should be regarded as an individual therapeutic trial. Realistic goals of therapy have to be defined. All patients must be kept under close clinical surveillance. As with any other medical therapy, if the treatment fails to reach the predefined goals and/or the patient is additionally burdened by an unacceptable level of adverse effects and/or there are signs of abuse and misuse of the drug by the patient, therapy with cannabis-based medicines should be terminated. Significance: This position paper provides expert recommendations for nonspecialist and specialist healthcare professionals in Europe, on the importance and the appropriate use of cannabis-based medicines as part of a multidisciplinary approach to pain management, in properly selected and supervised patients.

Original languageEnglish
Pages (from-to)1547-1564
Number of pages18
JournalEuropean Journal of Pain (United Kingdom)
Volume22
Issue number9
DOIs
Publication statusPublished - Oct 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management'. Together they form a unique fingerprint.

Cite this